This outcome aligns with our expectations, as dabrafenib is an FDA‐approved therapeutic agent for patients with unresectable or metastatic melanoma harboring the BRAF V600E mutation.[30] Similarly, the drug's lowest ranking in the HRAS‐mutant sample (GSM6022252) is also consistent with our expectations (Figure S8B, Supporting Information). The gene discussed is BRAF; the disease is metastatic melanoma.